"Pathological response" trang 1 - tải miễn phí từ tailieunhanh
A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer
9    47    1
Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy

Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy
8    64    1
Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer

Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer
10    47    1
Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: A real-world study

Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: A real-world study
10    8    1
Predictive factors of disease-free survival after complete pathological response to neoadjuvant radiotherapy for rectal adenocarcinoma: Retrospective case series

Predictive factors of disease-free survival after complete pathological response to neoadjuvant radiotherapy for rectal adenocarcinoma: Retrospective case series
7    94    0
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer

Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer
8    79    2
Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review

Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review
8    37    1
A nomogram based on platelet-tolymphocyte ratio for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy

A nomogram based on platelet-tolymphocyte ratio for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy
9    2    1
Develop and validate a radiomics space-time model to predict the pathological complete response in patients undergoing neoadjuvant treatment of rectal cancer: An artificial intelligence model study based on machine learning

Develop and validate a radiomics space-time model to predict the pathological complete response in patients undergoing neoadjuvant treatment of rectal cancer: An artificial intelligence model study based on machine learning
11    7    1
Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer

Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer
11    95    0
CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy
11    66    0
Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients

Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients
12    44    1
Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response

Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response
12    97    0
Predicting the response to neoadjuvant chemotherapy for breast cancer: Wavelet transforming radiomics in MRI

Predicting the response to neoadjuvant chemotherapy for breast cancer: Wavelet transforming radiomics in MRI
10    74    0
RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial

RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial
7    75    0
Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer

Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer
10    43    1
Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy

Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy
6    54    1
A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): Rationale and design

A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): Rationale and design
8    48    1
Survival landscape of different tumor regression grades and pathologic complete response in rectal cancer after neoadjuvant therapy based on reconstructed individual patient data

Survival landscape of different tumor regression grades and pathologic complete response in rectal cancer after neoadjuvant therapy based on reconstructed individual patient data
11    41    1
The CHASIT study: Sequential chemoimmunotherapy in patients with locally advanced urothelial cancer – a nonrandomized phase II clinical trial

The CHASIT study: Sequential chemoimmunotherapy in patients with locally advanced urothelial cancer – a nonrandomized phase II clinical trial
6    8    1